eBooks & Guides

Going small to win big: Fragment-based screening in drug discovery

Issue link: https://resources.nanotempertech.com/i/1133236

Contents of this Issue

Navigation

Page 9 of 20

10 Gives you K d , handles a broad range of molecule types, measures in solution with very little sample and very low maintenance Doesn't provide kinetic constants (K off and K on ) and fluorescent labeling of one of the binding partners is typically required environment is altered via any conformational change or ligand proximity 6 resulting in a quantifiable, binding-dependent fluorescence variation. This variation is measured and used to calculate the strength of the molecular interaction or equilibrium dissociation constant (K d ) in an accurate way. With TRIC it's possible to study the interactions between a multitude of molecules (proteins, ions, nucleic acids, sugars, etc.) and also evalute a very broad range of interaction strengths (pico to millimolar). In addition, one can label the target with fluorophores that are particularly sensitive to binding events, resulting in better signal amplitudes and signal-to- noise ratios 2 . Experiments where TRIC is the major component of the MST signal measured were used in small molecule or fragment screening campaigns as an alternative to surface-based techniques 17 . TRIC can quantify interactions in the presence of organic solvents like DMSO 3 , in cell lysates 16 or liposomes and nanodiscs 8 . With measurements taking place in solution in close-to-native conditions, the concern of false positives that occur with NSB of compounds to immobilization surfaces is eliminated. Recently it was shown that interactions can be quantified under conditions where the measured signal was derived entirely from TRIC 14 . The benefit of this approach is clear for FBDD — flexible throughput, fast time to results, and a 384-well plate format — all desirable attributes for screening campaigns.

Articles in this issue

view archives of eBooks & Guides - Going small to win big: Fragment-based screening in drug discovery